Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level.

Tabor A, Weisenburger S, Banerjee A, Purkayastha N, Kaindl JM, Hübner H, Wei L, Grömer TW, Kornhuber J, Tschammer N, Birdsall NJ, Mashanov GI, Sandoghdar V, Gmeiner P.

Sci Rep. 2016 Sep 12;6:33233. doi: 10.1038/srep33233.

2.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

3.

Abundance, distribution, mobility and oligomeric state of M₂ muscarinic acetylcholine receptors in live cardiac muscle.

Nenasheva TA, Neary M, Mashanov GI, Birdsall NJ, Breckenridge RA, Molloy JE.

J Mol Cell Cardiol. 2013 Apr;57:129-36. doi: 10.1016/j.yjmcc.2013.01.009. Epub 2013 Jan 25.

4.

Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.

Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, Tran T, Dransfield PJ, Brown SP, Houze J, Vimolratana M, Jiao XY, Wang Y, Birdsall NJ, Swaminath G.

Mol Pharmacol. 2012 Nov;82(5):843-59. doi: 10.1124/mol.112.079640. Epub 2012 Aug 2.

5.

Class A GPCR heterodimers: evidence from binding studies.

Birdsall NJ.

Trends Pharmacol Sci. 2010 Nov;31(11):499-508. doi: 10.1016/j.tips.2010.08.003. Epub 2010 Oct 1. Review. Erratum in: Trends Pharmacol Sci. 2011 Jan;32(1):1.

PMID:
20870299
6.

Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.

Benson N, Snelder N, Ploeger B, Napier C, Sale H, Birdsall NJ, Butt RP, van der Graaf PH.

Br J Pharmacol. 2010 May;160(2):389-98. doi: 10.1111/j.1476-5381.2010.00719.x.

7.

Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules.

Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, Molloy JE, Birdsall NJ.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8. doi: 10.1073/pnas.0907915107. Epub 2010 Jan 20.

8.

Different interactions between MT7 toxin and the human muscarinic M1 receptor in its free and N-methylscopolamine-occupied states.

Fruchart-Gaillard C, Mourier G, Marquer C, Stura E, Birdsall NJ, Servent D.

Mol Pharmacol. 2008 Dec;74(6):1554-63. doi: 10.1124/mol.108.050773. Epub 2008 Sep 10.

PMID:
18784346
9.

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.

10.

Pharmacological characterisation of strychnine and brucine analogues at glycine and alpha7 nicotinic acetylcholine receptors.

Jensen AA, Gharagozloo P, Birdsall NJ, Zlotos DP.

Eur J Pharmacol. 2006 Jun 6;539(1-2):27-33. Epub 2006 May 9.

PMID:
16687139
11.

Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.

Tränkle C, Dittmann A, Schulz U, Weyand O, Buller S, Jöhren K, Heller E, Birdsall NJ, Holzgrabe U, Ellis J, Höltje HD, Mohr K.

Mol Pharmacol. 2005 Dec;68(6):1597-610. Epub 2005 Sep 12.

PMID:
16157694
12.

Allosterism at muscarinic receptors: ligands and mechanisms.

Birdsall NJ, Lazareno S.

Mini Rev Med Chem. 2005 Jun;5(6):523-43. Review.

PMID:
15974931
13.
14.

Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2003;20(3):363-7.

PMID:
14501021
15.

Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.

Tränkle C, Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJ, Mohr K.

Mol Pharmacol. 2003 Jul;64(1):180-90.

PMID:
12815174
16.

Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors.

Lazareno S, Popham A, Birdsall NJ.

Mol Pharmacol. 2002 Dec;62(6):1492-505.

PMID:
12435818
17.

Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):123-7.

PMID:
12212769
18.

Substituted pentacyclic carbazolones as novel muscarinic allosteric agents: synthesis and structure-affinity and cooperativity relationships.

Gharagozloo P, Lazareno S, Miyauchi M, Popham A, Birdsall NJ.

J Med Chem. 2002 Mar 14;45(6):1259-74.

PMID:
11881995
19.

Multiple allosteric sites on muscarinic receptors.

Birdsall NJ, Lazareno S, Popham A, Saldanha J.

Life Sci. 2001 Apr 27;68(22-23):2517-24. Review.

PMID:
11392621
20.
22.

Reply: effect of radioligand contamination on the analysis of homologous competition experiments

Lazareno S, Birdsall NJ.

Trends Pharmacol Sci. 2000 May;21(5):169. No abstract available.

PMID:
10785648
23.

Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor.

Leppik RA, Mynett A, Lazareno S, Birdsall NJ.

Mol Pharmacol. 2000 Mar;57(3):436-45.

PMID:
10692482
24.

Effects of contamination on radioligand binding parameters.

Lazareno S, Birdsall NJ.

Trends Pharmacol Sci. 2000 Feb;21(2):57-60.

PMID:
10664609
25.

Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.

Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M.

Mol Pharmacol. 1999 Apr;55(4):778-86.

PMID:
10101037
26.

Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.

Lazareno S, Birdsall B, Fukazawa T, Gharagozloo P, Hashimoto T, Kuwano H, Popham A, Sugimoto M, Birdsall NJ.

Life Sci. 1999;64(6-7):519-26.

PMID:
10069518
27.

Allosteric interactions of quaternary strychnine and brucine derivatives with muscarinic acetylcholine receptors.

Gharagozloo P, Lazareno S, Popham A, Birdsall NJ.

J Med Chem. 1999 Feb 11;42(3):438-45.

PMID:
9986715
28.

Muscarinic interactions of bisindolylmaleimide analogues.

Lazareno S, Popham A, Birdsall NJ.

Eur J Pharmacol. 1998 Nov 6;360(2-3):281-4.

PMID:
9851596
29.

International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Caulfield MP, Birdsall NJ.

Pharmacol Rev. 1998 Jun;50(2):279-90. Review. No abstract available.

PMID:
9647869
30.
31.

Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies.

Lazareno S, Gharagozloo P, Kuonen D, Popham A, Birdsall NJ.

Mol Pharmacol. 1998 Mar;53(3):573-89. Erratum in: Mol Pharmacol 1999 Jan;55(1):194.

PMID:
9495826
32.

Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging.

Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, Oakley AE, Ince PG, Perry EK, Perry RH.

Brain Res Dev Brain Res. 1997 Jul 18;101(1-2):93-105.

PMID:
9263584
33.

To what extent can binding studies allow the quantification of affinity and efficacy?

Birdsall NJ, Lazareno S.

Ann N Y Acad Sci. 1997 May 30;812:41-7. Review. No abstract available.

PMID:
9186719
34.

Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes.

Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, Popham A, Sugimoto M.

Life Sci. 1997;60(13-14):1047-52. Review.

PMID:
9121346
35.

The affinity of adenosine for the high- and low-affinity states of the human adenosine A1 receptor.

Cohen FR, Lazareno S, Birdsall NJ.

Eur J Pharmacol. 1996 Aug 1;309(1):111-4.

PMID:
8864701
36.

The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.

Cohen FR, Lazareno S, Birdsall NJ.

Br J Pharmacol. 1996 Apr;117(7):1521-9.

37.

Allosteric regulation of muscarinic receptors.

Birdsall NJ, Lazareno S, Matsui H.

Prog Brain Res. 1996;109:147-51. Review. No abstract available.

PMID:
9009701
38.

The role of the cholinergic system in the development of the human cerebellum.

Court JA, Perry EK, Spurden D, Griffiths M, Kerwin JM, Morris CM, Johnson M, Oakley AE, Birdsall NJ, Clementi F, et al.

Brain Res Dev Brain Res. 1995 Dec 21;90(1-2):159-67.

PMID:
8719339
40.

Allosteric regulation of G-protein-linked receptors.

Birdsall NJ, Cohen F, Lazareno S, Matsui H.

Biochem Soc Trans. 1995 Feb;23(1):108-11. Review. No abstract available.

PMID:
7758667
41.

Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.

Matsui H, Lazareno S, Birdsall NJ.

Mol Pharmacol. 1995 Jan;47(1):88-98.

PMID:
7838137
42.

Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors.

Spalding TA, Birdsall NJ, Curtis CA, Hulme EC.

J Biol Chem. 1994 Feb 11;269(6):4092-7.

45.
47.

Wheel on the sweet smell of success.

Birdsall NJ.

Trends Pharmacol Sci. 1991 Aug;12(8):283-5. Review. No abstract available.

PMID:
1949195
48.

Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes.

Pedder EK, Eveleigh P, Poyner D, Hulme EC, Birdsall NJ.

Br J Pharmacol. 1991 Jun;103(2):1561-7.

49.

Cloning and structure-function of the H2 histamine receptor.

Birdsall NJ.

Trends Pharmacol Sci. 1991 Jan;12(1):9-10. Review. No abstract available.

PMID:
2006542
50.

Use of clonal cell lines in the analysis of neurotransmitter receptor mechanisms and function.

Buckley NJ, Hulme EC, Birdsall NJ.

Biochim Biophys Acta. 1990 Oct 15;1055(1):43-53. Review. No abstract available.

PMID:
2171675

Supplemental Content

Loading ...
Support Center